According to Heron Therapeutics's latest financial reports the company's current earnings (TTM) are -$0.12 B. In 2022 the company made an earning of -$0.19 B an increase over its 2021 earnings that were of -$0.23 B.The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Year | Earnings | Change |
---|---|---|
2023 (TTM) | -$0.12 B | -39.26% |
2022 | -$0.19 B | -17.52% |
2021 | -$0.23 B | -2.9% |
2020 | -$0.23 B | 11% |
2019 | -$0.21 B | 14.49% |
2018 | -$0.18 B | -9.44% |
2017 | -$0.2 B | 14.06% |
2016 | -$0.18 B | 77.42% |
2015 | -$97.6 M | 27.79% |
2014 | -$76.37 M | 38.14% |
2013 | -$55.29 M | 126.29% |
2012 | -$24.43 M | 114.52% |
2011 | -$11.39 M | 14.64% |
2010 | -$9.94 M | -2.92% |
2009 | -$10.24 M | -55.6% |
2008 | -$23.05 M | 2.46% |
2007 | -$22.5 M | 19.23% |
2006 | -$18.87 M | 122.61% |
2005 | -$8.48 M | -9.04% |
2004 | -$9.32 M | 40.92% |
2003 | -$6.62 M | 48.97% |
2002 | -$4.44 M | -23.18% |
2001 | -$5.78 M |
Company | Earnings | Earnings differencediff. | Country |
---|---|---|---|
SurModics SRDX | $13.33 M | -112.06% | ๐บ๐ธ USA |
Pacira Biosciences
PCRX | $61.7 M | -155.81% | ๐บ๐ธ USA |
Ligand Pharmaceuticals LGND | $64.31 M | -158.17% | ๐บ๐ธ USA |
Alkermes ALKS | $0.44 B | -502.09% | ๐ฎ๐ช Ireland |
Nektar Therapeutics
NKTR | -$0.28 B | 149.87% | ๐บ๐ธ USA |